Rescue Hearing Inc. Expands Scientific Advisory Board with the signing of Dr. Jeffrey Holt

GAINESVILLE– March 12, 2020– Rescue Hearing Inc., a team of visionary, internationally recognized physicians, scientists, and bioengineers focused on developing new gene therapies to eliminate hearing loss, announced the signing of Dr. Jeffrey Holt to its Scientific Advisory Board today.

“Dr. Holt has been working in the hearing loss science field for many years and has a wealth of experience, ” RHI CEO and Founder Jim Alaya said. “The scientific team here at RHI share a passion for translational science and getting our therapies to patients that need them.  Jeff fits in well with our team, our culture, and we are honored to have him join our team.”

Dr. Holt brings 20 years of valuable experience to Rescue Hearing Inc. Currently, he is a scientist at Boston Children’s Hospital and a professor of Otolaryngology and Neurology at Harvard Medical School. Dr. Holt received his Ph.D. from the Department of Physiology at the University of Rochester. He then completed a postdoctoral fellowship with the Howard Hughes Medical Institute at Harvard Medical School. Dr. Holt worked within the Neuroscience department at the University of Virginia and later returned to Harvard where he is the Director of Research in the Department of Otolaryngology. He also carries out research for the F.M. Kirby Neurobiology Center and the Neurobiology Program at Boston Children’s Hospital.

“The Rescue Hearing team brings a talented group of scientists and physicians together with a single sharply focus goal, development of therapeutic strategies for treating genetic hearing loss,” Dr. Holt said. “This collaborative team works with the highest of scientific and ethical standards for the benefit of patients. It is an honor for me to be part of this group and bring my expertise and perspective to this extraordinary and noble effort.”

About Rescue Hearing Inc.

Rescue Hearing Inc. combines the top physicians and researchers with cutting-edge technologies in gene therapy and diagnostics to develop a diversified asset portfolio. The RHI team has spent years developing and maintaining relationships with professionals in the field of hearing loss. RHI depends on this network to develop the initial platform technology in the hearing loss vertical.


Jim Ayala



Leave a Comment

Your email address will not be published. Required fields are marked *